727737-00-0Relevant articles and documents
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors
Aik, Wei Shen,Brown, Tom,Clunie-O'Connor, Caitlin,Demetriades, Marina,El-Sagheer, Afaf H.,Leissing, Thomas M.,Leung, Ivanhoe K. H.,Maheswaran, Pratheesh,McDonough, Michael A.,Ng, Yi Min,Salah, Eidarus,Schofield, Christopher J.,Shishodia, Shifali,Tam, Nok Yin,Tumber, Anthony,Zhang, Dong
, p. 16609 - 16625 (2021/11/24)
FTO catalyzes the Fe(II) and 2-oxoglutarate (2OG)-dependent modification of nucleic acids, including the demethylation of N6-methyladenosine (m6A) in mRNA. FTO is a proposed target for anti-cancer therapy. Using information from crystal structures of FTO
HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
Paragraph 0141; 0142, (2018/01/11)
The invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.
TANK-BINDING KINASE INHIBITOR COMPOUNDS
-
Page/Page column 64, (2015/12/24)
Compounds having the following formula (I) and methods of their use and preparation are disclosed:
